Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 4 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) Overview | 7 | 1 |
| Therapeutics Development | 8 | 3 |
| Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) Products under Development by Stage of Development | 8 | 1 |
| Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) Products under Development by Therapy Area | 9 | 1 |
| Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) Products under Development by Indication | 10 | 1 |
| Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) Pipeline Products Glance | 11 | 2 |
| Late Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) Products under Development by Companies | 13 | 2 |
| Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) Therapeutics Assessment | 15 | 5 |
| Assessment by Monotherapy/Combination Products | 15 | 1 |
| Assessment by Mechanism of Action | 16 | 1 |
| Assessment by Route of Administration | 17 | 2 |
| Assessment by Molecule Type | 19 | 1 |
| Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) Companies Involved in Therapeutics Development | 20 | 8 |
| Daiichi Sankyo Company, Limited | 20 | 1 |
| Galmed Pharmaceuticals Ltd | 21 | 1 |
| GlaxoSmithKline Plc | 22 | 1 |
| Johnson &Johnson | 23 | 1 |
| Novartis AG | 24 | 1 |
| Sanofi | 25 | 1 |
| Thesan Pharmaceuticals, Inc. | 26 | 1 |
| Xenon Pharmaceuticals Inc. | 27 | 1 |
| Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) Drug Profiles | 28 | 13 |
| Aramchol Drug Profile | 28 | 5 |
| GSK-1940029 Drug Profile | 33 | 1 |
| SAR-224 Drug Profile | 34 | 1 |
| Small Molecule to Inhibit SCD-1 for Nonalcoholic Steatohepatitis Drug Profile | 35 | 1 |
| Small Molecule to Inhibit SCD1 for Metabolic Disorders Drug Profile | 36 | 1 |
| Small Molecule to Inhibit Stearoyl-CoA Desaturase-1 for Obesity Drug Profile | 37 | 1 |
| Small Molecules to Inhibit SCD1 for Metastatic Renal Cell Carcinoma Drug Profile | 38 | 1 |
| TSN-2898 Drug Profile | 39 | 1 |
| XEN-801 Drug Profile | 40 | 1 |
| Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) Dormant Projects | 41 | 1 |
| Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) Discontinued Products | 42 | 1 |
| Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) Featured News &Press Releases | 43 | 11 |
| Jun 07, 2016: Galmed Pharmaceuticals Expands its Ongoing Phase IIb ARREST Study to China | 43 | 1 |
| Jun 01, 2016: Galmed Pharmaceuticals Randomizes 120th Patient in the ARREST Trial | 43 | 1 |
| Mar 30, 2016: Aramchol Demonstrates Significant Anti-Fibrotic Effect in a Pre-clinical Model of Fatty Liver Disease | 44 | 1 |
| Mar 01, 2016: Galmed Pharmaceuticals Announces the Enrollment of the First Patient in the ARRIVE Study | 45 | 1 |
| Feb 10, 2016: Xenon Initiates Phase 2 Clinical Trial of XEN801 to Treat Moderate to Severe Acne | 45 | 1 |
| Dec 01, 2015: Galmed Pharmaceuticals Announces FDA Clearance of IND of Aramachol for the Treatment of Patients with HIV-Associated Lipodystrophy and Nonalcoholic Fatty Liver Disease | 46 | 1 |
| Sep 24, 2015: Xenon Pharmaceuticals Announces Initiation of XEN801 Phase 1 Clinical Trial | 47 | 1 |
| Aug 13, 2015: Galmed Pharmaceuticals Announces the Commencement of Patient Screening in the ARREST Study in the United States and Latin America | 47 | 1 |
| Mar 09, 2015: Galmed Pharmaceuticals Announces the Beginning of Enrollment in its Phase IIb ARREST Trial for the Treatment of NASH, as well as the Expansion of the Study to the United States | 48 | 1 |
| Jan 28, 2015: Galmed and Perrigo Execute Manufacturing Agreement for Large-Scale Aramchol API Production | 49 | 1 |
| Dec 01, 2014: Galmed Pharmaceuticals Completes Analysis of a Pharmacokinetic Study of Aramchol in Healthy Volunteers | 49 | 1 |
| Nov 13, 2014: Galmed Pharmaceuticals Announces First Administration of Aramchol in its Phase IIa Trial for the Treatment of Cholesterol Gallstones | 50 | 1 |
| Sep 23, 2014: Galmed Pharmaceuticals Announces U.S. FDA Approval of Fast Track Designation of Aramchol for the Treatment of NASH | 50 | 1 |
| Sep 02, 2014: Galmed Pharmaceuticals Completes Two Chronic Toxicology Studies and Reports No Significant Adverse Events | 51 | 1 |
| Jul 22, 2014: Galmed Announces FDA Clearance of IND of Armachol for the Treatment of Fatty Liver Disorders | 52 | 2 |
| Appendix | 54 | 2 |
| Methodology | 54 | 1 |
| Coverage | 54 | 1 |
| Secondary Research | 54 | 1 |
| Primary Research | 54 | 1 |
| Expert Panel Validation | 54 | 1 |
| Contact Us | 54 | 1 |
| Disclaimer | 55 | 1 |